Neuregulin-1 expression correlates with sensitivity to the PI3K inhibitor, GDC-0032, outside of PIK3CA mutations in head and neck cancer

被引：0
|
作者：
Savage, Heidi M. [1 ]
O'Brien, Carol [1 ]
Yauch, Bob [1 ]
Settleman, Jeff [1 ]
Lackner, Mark R. [1 ]
Wilson, Timothy R. [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-2631
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2631
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations
    Zumsteg, Zachary S.
    Morse, Natasha
    Krigsfeld, Gabriel
    Gupta, Gaorav
    Higginson, Daniel S.
    Lee, Nancy Y.
    Morris, Luc
    Ganly, Ian
    Shiao, Stephan L.
    Powell, Simon N.
    Chung, Christine H.
    Scaltriti, Maurizio
    Baselga, Jose
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (08) : 2009 - 2019
  • [2] Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors.
    Olivero, Alan G.
    Heffron, Timothy P.
    Baumgardner, Matthew
    Belvin, Marcia
    Ross, Leanne Berry
    Blaquiere, Nicole
    Bradley, Erin
    Castanedo, Georgette
    Derynck, Mika
    Do, Steven
    Dotson, Jennafer
    Dudley, Danette
    Edgar, Kyle
    Folkes, Adrian
    Francis, Ross
    Gianetti, Tony
    Goldsmith, Richard
    Goldsmith, Paul
    Guan, Jane
    Harrison, Trevor
    Heald, Robert
    Hsu, Jerry
    Jackson, Phillip
    Jones, Graham
    Kim, Amy
    Kolesnikov, Aleks
    Lackner, Mark
    Lee, Leslie
    Lesnick, John
    Lewis, Cristina
    Mamounas, Michael
    McLean, Neville
    Murray, Jeremy
    Ndubaku, Chudi
    Nonomiya, Jim
    Pang, Jodie
    Pegg, Neil
    Prior, Wei Wei
    Salphati, Laurent
    Sampath, Deepack
    Sideris, Stephen
    Siu, Michael
    Staben, Steven
    Sutherlin, Daniel
    Ultsch, Mark
    Wallin, Jeff
    Wang, Lan
    Wiesmann, Christian
    Zhang, Xiaolin
    Friedman, Lori S.
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [3] The PI3K inhibitor, taselisib (GDC-0032), has enhanced potency in PIK3CA mutant models through a unique mechanism of action
    Edgar, Kyle A.
    Song, Kyung
    Schmidt, Stephen
    Kirkpatrick, Don
    Phu, Lilian
    Nannini, Michelle
    Hong, Rebecca
    Cheng, Eric
    Young, Amy
    Sampath, Deepak
    Friedman, Lori S.
    [J]. CANCER RESEARCH, 2016, 76
  • [4] Development of a predictive biomarker gene expression signature for the PIK3CA inhibitor, GDC-0032, in breast cancer cells
    Savage, H.
    O'Brien, C.
    Spoerke, J.
    Huw, L.
    Wallin, J.
    Friedman, L.
    Lackner, M. R.
    Wilson, T. R.
    [J]. CANCER RESEARCH, 2013, 73
  • [5] PI3K expression and PIK3CA mutations are related to colorectal cancer metastases
    Zhu, Yu-Fen
    Yu, Bao-Hua
    Li, Da-Li
    Ke, Hong-Lin
    Guo, Xian-Zhi
    Xiao, Xiu-Ying
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (28) : 3745 - 3751
  • [6] PI3K expression and PIK3CA mutations are related to colorectal cancer metastases
    Yu-Fen Zhu
    [J]. World Journal of Gastroenterology, 2012, (28) : 3745 - 3751
  • [7] Phase I evaluation of the PI3 kinase (PI3K) inhibitor taselisib (GDC-0032) in multiple locally advanced or metastatic PIK3CA mutant solid tumor types.
    Jhaveri, Komal L.
    Bedard, Philippe L.
    Cejalvo, Juan Miguel
    Hart, Lowell L.
    Juric, Dejan
    Kelly, Karen
    Lockhart, A. Craig
    Melnyk, Anton
    Moore, Kathleen N.
    Nemunaitis, John J.
    Oliveira, Mafalda
    Patel, Manish R.
    Sachdev, Jasgit
    Smith, David
    VanderWalde, Ari
    Ware, Joseph A.
    Jin, Huan
    Wilson, Timothy R.
    Wei, Michael C.
    Baselga, Jose
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Circulating tumor DNA (ctDNA) analysis of PIK3CA and AKT1 mutations in patients enrolled onto the Phase 1b study of the PI3K inhibitor taselisib (GDC-0032) in solid malignancies
    Wilson, Timothy R.
    Savage, Heidi
    Aimi, Junko
    Jin, Jessica
    Parmar, Hema
    Hsu, Jerry
    Krop, Ian
    Saura, Cristina
    Cervantes, Andres
    Sachdev, Jasgit
    Patel, Manish
    Cejalvo, Juan
    Oliveira, Mafalda
    Winer, Eric
    Von Hoff, Daniel
    Baselga, Jose
    Juric, Dejan
    [J]. CANCER RESEARCH, 2015, 75
  • [9] GDC-0032, A Novel p110α Inhibitor, Specifically Radiosensitizes Head and Neck Squamous Cell Carcinomas Harboring Activating PIK3CA Alterations
    Zumsteg, Z. S.
    Morse, N.
    Higginson, D.
    Gupta, G.
    Morris, L.
    Ganly, I.
    Grandis, J.
    Lee, N. Y.
    Powell, S. N.
    Scaltriti, M.
    Baselga, J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S37 - S37
  • [10] The PI3K inhibitor GDC-0032 enhances the efficacy of standard of care therapeutics in PI3K alpha mutant breast cancer models
    Sampath, D.
    Nannini, M. A.
    Jane, G.
    Hong, R.
    Parsons, K. L.
    Belvin, M.
    Friedman, L. S.
    Wallin, J. J.
    [J]. CANCER RESEARCH, 2013, 73
12345